Skip to main content
NC Medicaid logo NC Medicaid

Topical Navigation

  • Home
  • Beneficiaries
  • Meetings & Notices
  • Find a Doctor
  • Providers
  • Counties
  • Reports
  • ABOUT US
  • NC.GOV
  • NCDHHS
  • SERVICES
NC Medicaid »   Home »   blog

SPECIAL BULLETIN COVID-19 #186: Booster Dose of Pfizer-BioNTech COVID-19 Vaccine CDC Recommendations and Medicaid and NC Health Choice Billing

September 27, 2021

On Sept. 24, 2021, the Centers for Disease Control and Prevention (CDC) recommended:

  • people 65 years and older and residents in long-term care settings should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, 
  • people aged 50–64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, 
  • people aged 18–49 years with underlying medical conditions may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks, and 
  • people aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks. 

More information on the CDC’s recommendations can be found here.  More information on the FDA’s authorization can be found here.

The Pfizer-BioNTech vaccine booster dose is approved for people 18 years and older and is different from the FDA approved third dose of the Pfizer vaccine which is approved for the immunocompromised population.

The recommendations for the booster shot vaccine only applies to people who previously received a Pfizer-BioNTech primary series (i.e., the first two doses of a COVID-19 vaccine). Medicaid beneficiaries should talk to their healthcare provider about whether getting a Pfizer-BioNTech COVID-19 booster shot is appropriate for them.

Beginning Sept. 24, 2021, NC Medicaid vaccine providers may begin administering the booster dose of mRNA COVID-19 vaccine to those beneficiaries who qualify and by self-attestation.

Payment amount will be equivalent as for other doses of the COVID-19 vaccine at $40.00 each. 

For Medicaid and NC Health Choice Billing

  • The ICD-10-CM diagnosis code required for billing is:  Z23 - Encounter for immunization
  • Providers must bill with HCPCS code: 
    • 91300 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
  • The maximum reimbursement rate per unit is: N/A (only administration charge will be reimbursed)
  • Claims must have appropriate NDCs, which correspond to the vaccine used for administration and corresponding CPT code 
  • Claims must contain both administration codes and vaccine codes to pay
  • Vaccine codes should be reported as $0.00
  • Medicaid and NC Health Choice does not allow copays to be charged for COVID-19 immunization or administrations
  • COVID-19 vaccines are exempt from the Vaccines for Children (VFC) program
  • TJ modifier should be used for NC Health Choice claims (age 6 through 18 years)
  • EP modifier should be used for all non-NC Health Choice (only Medicaid beneficiaries) younger than 21 years of age
  • CG modifier should be used for claims submitted by a pharmacy participating in the immunization program for both the vaccine and administration codes

COVID-19 Vaccine Billing Codes for Medicaid Beneficiaries

Vaccine CPT Codes to Report

Vaccine CPT Code to Report NDC  CPT Code Description
91300 59267-1000-01
59267-1000-02 
59267-1000-03
 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use

 

Vaccine CPT Code Administration CPT Code CPT Code Description 
91300 0001A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
91300 0002A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose
91300 0004A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: Booster

 

Please see the updated Interim Clinical Considerations for use of COVID-19 Vaccines Currently Authorized in the United States for more details.

Other Resources and Links

  • Pfizer EUA
  • Pfizer Health Care Provider Fact Sheet
  • Pfizer Fact Sheet for Recipients
     

CONTACT

NCTracks Contact Center: 800-688-6696

 

This blog is related to:

  • Bulletins
  • Pharmacy Providers
  • Physicians, Physician Assistants and Nurse Practitioners

Related Articles

  • Billing Requirement Modifications Due to COVID-19 to Expire
  • Verifying Provider Information (NPI+Location Code) in NCTracks
  • Lutetium Lu 177 Vipivotide Tetraxetan Injection, for Intravenous Use (Pluvicto™) HCPCS Code A9699: Billing Guidelines
  • Kit for the Preparation of Gallium Ga 68 Dotatate Injection, for Intravenous Use (Netspot®) HCPCS Code A9587: Billing Guidelines
  • Kit for the Preparation of Gallium Ga 68 Gozetotide Injection, for Intravenous Use (Locametz®) HCPCS Code A9597: Billing Guidelines
  • Gadoterate Meglumine Injection, for Intravenous Use (Clariscan™) HCPCS Code A9575: Billing Guidelines
  • Free Dental Continuing Education Credits
  • Ephedrine Hydrochloride Injection, for Intravenous use (Rezipres®) HCPCS code J3490: Billing Guidelines
  • Filgrastim-ayow Injection, for Subcutaneous or Intravenous Use (Releuko®) HCPCS Code J3590: Billing Guidelines
  • Nivolumab and Relatlimab-rmbw Injection, for Intravenous Use (Opdualag™) HCPCS Code J9999: Billing Guidelines
  • Difelikefalin Injection, for Intravenous use (Korsuva™) HCPCS code J0879 - Injection, difelikefalin, 0.1 microgram, (for ESRD on Dialysis): Billing Guidelines
  • Sutimlimab-jome Injection, for Intravenous Use (Enjaymo™) HCPCS Code J3590: Billing Guidelines
  • One Year Anniversary of New Service to Ensure Communication Access in Health Care Settings
  • SPECIAL BULLETIN COVID-19 #247: Over-the-Counter COVID-19 Tests for Home Use Pharmacy Coverage
  • Healthy Opportunities Housing and Transportation Services Available

Share this page:

  • Facebook
  • Twitter
  • Email
Back to top

Contact Information

NC Medicaid
Division of Health Benefits

2501 Mail Service Center
Raleigh, NC 27699-2501
 
NC Medicaid Contact Center
Phone: 888-245-0179
Monday-Friday 8 a.m. to 5 p.m.
Closed on State holidays. 
 
Visit RelayNC for information about TTY services. 
 
More
 

Recent Tweets

Tweets by @ncdhhs

Follow Us

  • Facebook
  • Twitter
  • YouTube
  • LinkedIn
  • EMPLOYEE DIRECTORY
  • TRANSLATION DISCLAIMER
  • Accessibility
  • Terms of Use
  • Privacy Policy
  • Open Budget
NC Medicaid
https://medicaid.ncdhhs.gov/blog/2021/09/27/special-bulletin-covid-19-186-booster-dose-pfizer-biontech-covid-19-vaccine